Bought a small pilot position in ARCTNASDAQ:ARCT prices gapped up on strong volume (10x the average) during the previous earnings before moving up to the $28 resistance level. The $28 price level served as resistance previously back during feb and april of last year so it was not surprising to see prices encountered resistance at that level. Prices moved sideways more or less at the top right side of the 1 year 3 months long base before it declined and undercut the pivot low of roughly $27. However, prices managed to find support at the 21EMA (green line). This is a positive sign that the stock is finding support. Prices formed a cheat entry but I missed out on the day of the breakout and only entered my position the day after (8 may).
While the entry was not right at the breakout level, i compensated it by taking a smaller than usual position in NASDAQ:ARCT due to its positive technical action. As the stock has moved up and above 1R, i have moved my stop loss to the entry price which gives me a free trade from here on. This means that even if prices move against me (as long as it does not gapped down which is a possibility), i'll breakeven on the trade. But if the stock moves up, I will be able to benefit from the upside. So i'm essentially taking on a risk free trade now.
ARCT
$ARCT is a BUY nowArcturus Therapeutics Holdings Inc. $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price. Moreover, the decline from ATH was 80% and the price has been in a sideways movement after it bottomed. With today's strong breakout of the descending channel, I am expecting the price to start its rise up to the upper band of the range-bound around $63. The long-term targets should be a lot higher.
The breakout setup entry provides us with an awesome +3 Reward/Risk. A tighter stop loss order can even make it a lot better. A late entry at current prices provides 1.8-2.0 which is still a good ratio.
BioTech stocks are risky and volatile. This is not financial advice. DYODD
Potential swing play on ARCTARCT fell a whopping 66% the past 2 days. The catalyst was the inability of its COVID vaccine to produce levels of antibodies comparable to other vaccines in development or already developed. You can check more here: www.investors.com
It found support around $41.5 and moved about 12% to the upside to only fall again. It is currently hovering over the $44.3 support level.
There is not much hope for a big rally to the upside on this stock unless they improve their vaccine. However, there might be a quick swing trade opportunity. Yesterday I bought the support at $41.5 and waited for a bounce, which happened today. I sold for a quick 10% profit. I am looking into entering again if it retraces to that level. If I enter, I will place a stop loss just below the wick of the big red candle that formed after the gap down, at around $39.5.
If this trade plays out well my upside targets are $47.5 and $50 (long term support/resistance levels).
***THE IDEAS SHARED HERE ARE MY OPINION. THIS IS NOT FINANCIAL ADVISE TO PLACE TRADES. PLEASE DO YOUR OWN RESEARCH AND ANALYSIS BEFORE BUYING/SELLING STOCKS.***